ICYMI, this week we had articles about a CME credit opportunity on the pathogenesis of HS, Paul Friedman, MD, reviewing UltraClear Laser-Coring, Journey Medical Corporation submitting its NDA for DFD-29 for the treatment of rosacea, and more.
Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.
Click here to view Dermatology Times' comprehensive list of health awareness days, months, weeks, and initiatives for 2024.
Click here to answer this week's poll.
Dermatology Times asked our readers to share what conferences they are looking forward to in the first quarter of 2024.
Test your knowledge of psoriasis treatment options with our 5-question quiz.
A late breaking session from Revolutionizing Atopic Dermatitis Virtual Conference analyzed the frequency and clinical meaningfulness of conjunctivitis.
This CME credit opportunity delves into the pathogenesis and management of hidradenitis suppurativa.
The work we do as caregivers is important, and it's equally important that we take care of ourselves.
Results of this study may also be indicative of oral orismilast's ability to contribute to meaningful clinical improvements, investigators noted.
In this week’s Pointers With Portela, the 208SkinDoc reveals his 5 essential acne care tips.
SKNJCT-003 is expected to enroll up to 60 patients.
Paul Friedman, MD, discusses the benefits of UltraClear Laser-Coring, patient downtime, how to decide what devices to have in your clinic, and more.
J3401 went into effect on January 1, 2024.
While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.
The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.
The Type C meeting held this past December involved discussion of a phase 3 clinical development plan for Ycanth in the treatment of common warts.
Soligenix shared today positive top-line data stemming from the phase 2a clinical trial.
In this study, researchers treated 37 basal cell carcinoma (BCC) lesions from 30 patients, with follow-ups at 5 time points after baseline examination.
The filing is supported by positive phase 3 clinical trial data.
The pilot study explored the use of double-conjugated retinoid serum used in combination with exfoliating peel pads.
The last patient has been dosed in the trial of the potential first-in-class oncolytic peptide for BCC.
Take a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.